Results 111 to 120 of about 134,036 (314)
Association is not causation: treatment effects cannot be estimated from observational data in heart failure [PDF]
, 2018 Aims: Treatment ‘effects’ are often inferred from non-randomized and observational studies. These studies have inherent biases and limitations, which may make therapeutic inferences based on their results unreliable.
Campbell, Ross T. +4 more
core +1 more source
Animal Models and Experimental Medicine, EarlyView.This narrative review discusses animal models of exosome‐based myocardial infarction treatments. Emerging techniques aim to improve exosome stability, targeting, and bioavailability for MI treatment as drug delivery vehicles and regenerative mediators that promote myocardial regeneration. Abstract Exosomes have emerged as promising therapeutic carriers,
Chayanisa Phutiyothin +2 more
wiley +1 more source
Effects of eprosartan on target organ protection
Vascular Health and Risk Management, 2006 Alejandro de la SierraHypertension Unit, Department of Internal Medicine, Hospital Clínic, IDIBAPS, University of Barcelona, SpainAbstract: Hypertension is the most important cardiovascular risk factor for stroke.
Alejandro de la Sierra
doaj
Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? [PDF]
, 2006 It has been postulated that endothelial cell injury is the initiating event in the pathogenesis of systemic sclerosis, causing attraction, attachment, migration and infiltration of activated T-cells and subsequent production of cytokines and growth ...
Derk, Chris T., Jimenez, Sergio A.
core +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid +2 more
wiley +1 more source
Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors [PDF]
Canadian Medical Association Journal, 2011 See related research article by McAlister and colleagues at [www.cmaj.ca/cgi/doi/10.1503/cmaj.101333][1]. In this issue, McAlister and colleagues looked at the safety of combining angiotensin-receptor blockers with angiotensin-converting-enzyme (ACE) inhibitors (combination therapy) using ...
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Present and Future in the Treatment of Diabetic Kidney Disease
Journal of Diabetes Research, 2015 Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression.
Borja Quiroga +2 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale +5 more
wiley +1 more source
Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure [PDF]
, 2018 This study aimed to compare the effect of β-blocker dose and heart rate (HR) on mortality in patients with heart failure with reduced ejection fraction (HFrEF).
Ajam, Samer +4 more
core +1 more source